BullFrog AI Holdings, Inc., a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced the appointment of Dr. Thomas W. Chittenden, PhD, DPhil, PStat, as its new Chief Scientific Officer. With a distinguished career at the intersection...
New Clinical AI care suites for Cardiology, Pulmonology, and Neurology; First-in-Class multi-modal predictive and Gen AI platform for research and clinical model development.
ConcertAI's TeraRecon, the #1 KLAS-ranked advanced visualization and AI Clinical SaaS solution, has announced that European healthcare providers now have access to its cardiology, pulmonology, and neurology...
Curia, a leading contract research, development and manufacturing organization, announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26. Lavezoli will lead Curia’s biologics division, overseeing its discovery, development and manufacturing services.
“This is an exciting time for our biologics team, and we are pleased to...
Opentrons Labworks, Inc., a leader in lab automation and makers of accessible lab robotics, announced the appointment of Gregory Cole, PhD as Chief Innovation Officer. With over a decade of medical robotics, IP strategy, and product commercialization expertise, Dr. Cole will be responsible for establishing commercial and academic partnerships...
Evaxion Biotech A/S, a clinical research-focused biotechnology company specializing in the development of vaccines powered by AI-Immunology™, announces the success of the initial phases of its collaboration with MSD in the field of vaccines (registered trademark of Merck & Co, Inc, Rahway, NJ, United States). The vaccine development project...
Absci Corporation, a data-first generative AI drug creation company, announced the initiation of IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody designed using Absci’s de novo generative AI foundation model. Given a target structure, Absci uses this model to designate a specific epitope of interest, allowing for the engineering...
ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, announced the successful initial use of its Artificial Intelligence (“AI”) program, named ADMAlytics. ADMAlytics combines AI and machine learning to improve and predict outcomes for production and operational processes. Recently, ADMA successfully produced...
Transformative, instrument-free solution for single cell RNA sequencing updated with improved sensitivity, faster workflow
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, announced a significant update to the company’s flagship Evercode™ Whole Transcriptome products. Available to ship in mid-March, Evercode Whole Transcriptome version 3 kits offer...
The research demonstrates a breakthrough in applying quantum-enhanced generative AI to drug discovery using today’s quantum devices.
Zapata Computing, Inc., the Industrial Generative AI company, today announced that its scientists, in collaboration with Insilico Medicine, the University of Toronto, and St. Jude Children’s Research Hospital have demonstrated the first instance...
AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced the launch of its latest global call for applications to identify computational biologists, biomedical scientists and inventors to form a new startup at AION...
